Andrew Left Says Mallinckrodt's Key Drug Could Be in Jeopardy
The drugmaker could be at risk as regulators begin to crack down on price hikes, Andrew Left says.
Mallinckrodt's (MNK) - Get Report most critical drug, Acthar Gel, has a long history of price hikes that could prove a liability for shareholders as watchdogs continue adding new pressure across the industry. Senate regulators recently have been gunning for drugmakers with a record of hiking drug prices. Short seller Andrew Left told Real Money that one of the most egregious drugs that could fall prey to regulators next could be Mallinckrodt's Acthar. 'I am not short the stock,' Left said in a phone interview with Fill or Kill, 'But there will be plenty of time to short the stock when the company gets the attention from Congress it deserves.'
Employees of TheStreet are restricted from owning individual securities.
